Skip to main content
Yifeng Pharmacy Chain Co., Ltd. logo

Yifeng Pharmacy Chain Co., Ltd. — Investor Relations & Filings

Ticker · 603939 ISIN · CNE100001TS5 LEI · 300300CZZIF44N1EZO06 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,865 across all filing types
Latest filing 2026-03-03 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603939

About Yifeng Pharmacy Chain Co., Ltd.

https://www.yfdyf.cn/

Yifeng Pharmacy Chain Co., Ltd. operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and sale of prescription drugs, over-the-counter medicines, traditional Chinese medicine, nutritional supplements, and medical devices. It utilizes a standardized management system across its extensive network of retail stores to ensure service quality and operational efficiency. Beyond physical retail, the company has developed a comprehensive digital healthcare ecosystem, integrating online-to-offline (O2O) services to provide professional pharmaceutical consultations and health management solutions. Its business model focuses on a "big health" strategy, aiming to provide accessible healthcare products and professional services to a broad consumer base through optimized supply chain logistics and a diversified product portfolio.

Recent filings

Filing Released Lang Actions
益丰药房关于使用闲置募集资金进行现金管理的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about the use of idle raised funds for cash management, specifically investing in structured deposits. It details the investment amount, types, risk analysis, approval procedures, and impact on the company. The document is relatively short (3424 characters) and focuses on the use of raised funds and related approvals rather than presenting financial statements or comprehensive financial data. It does not contain full financial reports or detailed financial statements. This type of document is typically classified as a Regulatory Filing (RNS) because it is a regulatory announcement about fund usage and investment activities, not a full financial report or earnings release.
2026-03-03 Chinese
益丰药房关于可转换公司债券付息的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the interest payment on a convertible bond issued by the company. It details the bond issuance, interest rates, payment dates, tax implications, and related administrative information. The content focuses on the bond interest payment schedule and procedures rather than financial results, management changes, or regulatory certifications. The document length is 4201 characters, which is relatively short but contains substantive information about the bond interest payment. This fits the category of a Capital/Financing Update (CAP), as it relates to financing activities and bond interest payments. It is not an Annual Report, Earnings Release, or Regulatory Filing, nor is it a report publication announcement. Therefore, the appropriate classification is CAP with high confidence.
2026-02-24 Chinese
益丰药房关于不向下修正“益丰转债”转股价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from the board of directors of Yifeng Pharmacy Chain Co., Ltd. regarding the decision not to downward adjust the conversion price of its convertible bonds (益丰转债). It details the bond issuance, the conditions triggering price adjustments, and the board's resolution not to adjust the conversion price despite the triggering conditions. The document is a formal disclosure about bond terms and board decisions related to convertible bond pricing, not a financial report, earnings release, or regulatory certification. It is a specific announcement about capital structure and bond terms, fitting the category of Capital/Financing Update (CAP). The document length is 2496 characters, which is typical for an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2026-02-05 Chinese
益丰药房关于使用闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of idle raised funds for cash management, specifically investing in structured deposits. It details the investment amount, types, risk analysis, approval procedures, and impact on the company. The document is relatively short (3616 characters) and focuses on a specific financing activity related to the use of raised funds rather than presenting comprehensive financial statements or a full report. It does not contain financial statements or detailed financial performance data. Therefore, it is best classified as a Capital/Financing Update (CAP) rather than an Annual Report, Interim Report, or other financial report types.
2026-02-03 Chinese
益丰药房关于预计触发“益丰转债”转股价格向下修正条件的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from the board of Yifeng Pharmacy Chain Co., Ltd. regarding the expected triggering of a downward adjustment condition for the conversion price of its convertible bonds (益丰转债). It details the bond issuance, terms, adjustment clauses, and the potential triggering event based on stock price performance. The document includes risk warnings and procedural information about the board's responsibilities upon triggering the adjustment. It is not a financial report, earnings release, or detailed investor presentation but a regulatory announcement about bond conversion price adjustments. The document length is 2658 characters, which is relatively short and focused on a specific event. This fits the category of a Capital/Financing Update (CAP) as it relates to convertible bond terms and potential price adjustments affecting capital structure and financing conditions.
2026-02-02 Chinese
益丰药房关于为控股子公司提供担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of guarantees provided by the company (益丰大药房连锁股份有限公司) for its controlling subsidiary. It includes specifics about guarantee amounts, counterparties, internal decision procedures, financial data of the subsidiary, and board opinions on the guarantees. The document is not a financial report, earnings release, or audit report. It is a regulatory announcement about financing-related guarantees and risk disclosures. The document length is 4467 characters, which is substantial and contains detailed information, not just a brief notice or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to updates on company financing activities and guarantees provided to subsidiaries.
2026-01-07 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.